Drug Profile
Research programme: small molecule therapeutics - Nimbus Therapeutics
Latest Information Update: 11 Jun 2020
Price :
$50
*
At a glance
- Originator Nimbus Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; CBLB protein expression inhibitors; Cytidine triphosphate synthetase inhibitors; DNA helicase inhibitors; KRAS protein inhibitors; MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer; Metabolic disorders
Most Recent Events
- 08 Jun 2020 Preclinical trials in Autoimmune disorders in USA (unspecified route)
- 08 Jun 2020 Preclinical trials in Cancer in USA (unspecified route)
- 08 Jun 2020 Preclinical trials in Metabolic disorders in USA (unspecified route)